12 Most Promising Small-Cap Stocks According to Wall Street Analysts

Page 11 of 11

1. Armata Pharmaceuticals, Inc. (NYSE:ARMP)

Armata Pharmaceuticals, Inc. (NYSE:ARMP) is among the most promising stocks.

On February 23, 2026, H.C. Wainwright increased the price target for ARMP from $9.00 to $15.00 and kept a Buy rating on the shares. The modification comes after the FDA designated AP-SA02 as a Qualified Infectious Disease Product, providing extra regulatory support as the business gets ready for its Phase 3 superiority research, which is set for the second half of 2026.

Armata Pharmaceuticals, Inc. (NYSE:ARMP) declared on February 23 that its intravenous Staphylococcus aureus multi-phage candidate, AP-SA02, has been given Qualified Infectious Disease Product (QIDP) classification by the U.S. FDA. Its usage as an adjuvant treatment for complex bacteremia brought on by both methicillin-sensitive (MSSA) and methicillin-resistant (MRSA) S. aureus is covered by the designation. In the second half of 2026, the company plans to place AP-SA02 into a Phase 3 superiority trial for complex bloodstream infections caused by S. aureus.

Armata Pharmaceuticals, Inc. (NYSE:ARMP) is a clinical-stage biotech company developing precision bacteriophage-based therapies to treat antibiotic-resistant and hard-to-treat bacterial infections, advancing a pipeline of pathogen-specific phage candidates from discovery through clinical trials.

While we acknowledge the potential of ARMP to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ARMP and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 14 Best GARP Stocks to Buy According to Analysts and 14 Best Affordable Dividend Stocks to Buy According to Analysts

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.

Page 11 of 11